Barriers of Treating EGFR-Mutant NSCLC With Adjuvant Osimertinib
Nathan Pennell, MD, PhD, discusses the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer.
Nathan Pennell, MD, PhD, a medical oncologist at the Cleveland Clinic, discusses the cost-effectiveness of adjuvant osimertinib (Tagrisso) in resected EGFR-mutant non-small cell lung cancer (NSCLC).
According to Pennell, at a 5% improvement in survival, osimertinib has a cost effectiveness ratio of $317,000, much higher than the commonly drug cost of $195,000 in the United States. This means, at the current cost, adjuvant osimertinib does not appear to be cost effective in this patient population.
However, the hope is that osimertinib turns out to be much more effective than previously reported, according to Pennell. If the effectiveness rate is between 25% to 30%, the agent would prove to be cost effective at the current standard. Additionally, if osimertinib was half the price, the drug would be cost-effective at 5%.
Zipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC
September 14th 2024Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.
Read More
